Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Solacy Pédiatrique
- Development stage
- Unknown
- Lead developer
- Laboratoires Grimberg
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules
- Administration
- Oral
01
Overview
Solacy Pédiatrique is an over-the-counter (OTC) combination drug developed by Laboratoires Grimberg for the symptomatic adjunctive treatment of nasopharyngeal disorders (such as rhinopharyngitis, rhinitis, and the common cold) in infants over 6 months of age and children. The formulation is delivered as a tablet for oral suspension and contains four active ingredients: L-cystine, precipitated sulfur, vitamin A (retinol acetate), and Saccharomyces cerevisiae yeast. This combination works synergistically to reduce inflammation of the rhinopharyngeal mucosa, while the presence of vitamin A provides immunostimulating properties to support the child's immune system during upper respiratory tract infections.
- Brand names
- Solacy PediatricSolacy Pédiatrique
- Other names
- L-cystine + retinol acetate + Saccharomyces cerevisiae + sulfurcystine + retinol + Saccharomyces cerevisiae + sulfurcystine + retinol + sulfur + yeast
Beyond the preview
Go deeper on Solacy Pédiatrique.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Solacy Pédiatrique.